Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Immunomodulators Market by Product (IMMUNOSUPPRESSANTS, IMMUNOSTIMULANTS) and by Application (Oncology, Respiratory, Human Immunodeficiency Virus (HIV), Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03495

Pages: NA

Charts: NA

Tables: NA

Immunomodulators are substances that alter the immune response by decreasing the responsiveness of the immune system to make antibodies or sensitized cells. These cells identify and react with the antigen that instigated their production. Some of the immunomodulators are corticosteroids, thymosin, cytotoxic agents, and immunoglobulins. Few of the immunomodulators are naturally present in the body, while some of these are obtained from pharmacological preparations.

The major factors that drive the market growth are increasing usage of monoclonal antibodies to treat diseases such as sclerosis, Crohns disease, rheumatoid arthritis & others, and the rising prevalence of cancer. In addition, availability of effective product pipeline of the companies involved in R&D of immunomodulators further fuels the market growth. However, the presence of stringent regulations involved in the approval procedure for immunomodulator antibodies pose entry difficulties for small-scale manufacturers, less availability of tumor necrosis factor (TNF) inhibitors, and high costs associated with them act as restraints for the market growth. In addition, rising awareness regarding the availability of such immunomodulators is anticipated to provide lucrative growth opportunities for the market.

The report segments the immunomodulators market based on product, application, and region. Based on product, the market is segmented into immunosuppressants and immunostimulants. Based on immunosuppressants, the market is segmented into antibodies, calcineurin inhibitors, glucocorticoids, antimetabolites, and others. Based on immunostimulants, the market is segmented into vaccines, antibodies, and others. Based on application, the market is segmented into oncology, respiratory, human immunodeficiency virus (HIV), and others. Regionally, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the immunomodulators market, with current trends and future estimations to elucidate imminent investment pockets.
  • It presents a quantitative analysis to enable stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by product type elucidates various forms of available immunomodulators.
  • Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.
  • By region, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

 Key Market Segments

  • By Product
    • IMMUNOSUPPRESSANTS
      • Antibodies
      • Calcineurin Inhibitors
      • Glucocorticoids
      • Antimetabolites
      • Others
    • IMMUNOSTIMULANTS
      • Vaccines
      • Antibodies
      • Others
  • By Application
    • Oncology
    • Respiratory
    • Human Immunodeficiency Virus (HIV)
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • India
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Argentina
      • Rest of LAMEA

 
Key Market Players

  • F. HOFFMANN-LA ROCHE LTD.
  • BIOGEN INC.
  • PFIZER INC.
  • MERCK & CO., INC.
  • AMGEN, INC.
  • ABBOTT LABORATORIES
  • BRISTOL-MYERS SQUIBB COMPANY
  • JOHNSON & JOHNSON
  • NOVARTIS AG
  • ELI LILLY AND COMPANY

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: IMMUNOMODULATORS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. IMMUNOSUPPRESSANTS

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Antibodies

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Calcineurin Inhibitors

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Glucocorticoids

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Antimetabolites

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Others

        • 4.2.4.1. Market Size and Forecast

    • 4.3. IMMUNOSTIMULANTS

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Vaccines

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Antibodies

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Others

        • 4.3.4.1. Market Size and Forecast

  • CHAPTER 5: IMMUNOMODULATORS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Oncology

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Respiratory

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Human Immunodeficiency Virus (HIV)

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: IMMUNOMODULATORS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Immunomodulators Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Immunomodulators Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Immunomodulators Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Immunomodulators Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Immunomodulators Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Immunomodulators Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Immunomodulators Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Immunomodulators Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Immunomodulators Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Immunomodulators Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Immunomodulators Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Immunomodulators Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Immunomodulators Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Immunomodulators Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Immunomodulators Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Immunomodulators Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Immunomodulators Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Immunomodulators Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Immunomodulators Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Immunomodulators Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Immunomodulators Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Immunomodulators Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Immunomodulators Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Immunomodulators Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Immunomodulators Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. F. HOFFMANN-LA ROCHE LTD.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. AMGEN, INC.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. ABBOTT LABORATORIES

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. JOHNSON And JOHNSON

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. NOVARTIS AG

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. BRISTOL-MYERS SQUIBB COMPANY

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. MERCK And CO., INC.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. ELI LILLY AND COMPANY

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. PFIZER INC.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. BIOGEN INC.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNOMODULATORS MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL IMMUNOMODULATORS MARKET FOR IMMUNOSUPPRESSANTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL IMMUNOMODULATORS MARKET FOR IMMUNOSTIMULANTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL IMMUNOMODULATORS MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL IMMUNOMODULATORS MARKET FOR ONCOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL IMMUNOMODULATORS MARKET FOR RESPIRATORY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL IMMUNOMODULATORS MARKET FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL IMMUNOMODULATORS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL IMMUNOMODULATORS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA IMMUNOMODULATORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 13. U.S. IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 14. U.S. IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 15. CANADA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 16. CANADA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 17. MEXICO IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 18. MEXICO IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE IMMUNOMODULATORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. FRANCE IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 23. FRANCE IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 24. GERMANY IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 25. GERMANY IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 26. ITALY IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 27. ITALY IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. SPAIN IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 29. SPAIN IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. UK IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 31. UK IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. RUSSIA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 33. RUSSIA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 34. REST OF EUROPE IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 35. REST OF EUROPE IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC IMMUNOMODULATORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. CHINA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 40. CHINA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. JAPAN IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 42. JAPAN IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 43. INDIA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 44. INDIA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 45. SOUTH KOREA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 46. SOUTH KOREA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. AUSTRALIA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 48. AUSTRALIA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 49. THAILAND IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 50. THAILAND IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 51. MALAYSIA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 52. MALAYSIA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. INDONESIA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 54. INDONESIA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA IMMUNOMODULATORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. BRAZIL IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 61. BRAZIL IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 62. SOUTH AFRICA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH AFRICA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 64. SAUDI ARABIA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 65. SAUDI ARABIA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. UAE IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 67. UAE IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 68. ARGENTINA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 69. ARGENTINA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 70. REST OF LAMEA IMMUNOMODULATORS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 71. REST OF LAMEA IMMUNOMODULATORS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 73. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 74. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 75. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 76. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. AMGEN, INC.: KEY EXECUTIVES
  • TABLE 78. AMGEN, INC.: COMPANY SNAPSHOT
  • TABLE 79. AMGEN, INC.: OPERATING SEGMENTS
  • TABLE 80. AMGEN, INC.: PRODUCT PORTFOLIO
  • TABLE 81. AMGEN, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 83. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 84. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 85. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 86. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 88. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 89. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 90. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 91. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 93. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 94. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 95. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 96. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 98. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 99. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
  • TABLE 100. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 101. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 103. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 104. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 105. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 106. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 108. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 109. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 110. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 111. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. PFIZER INC.: KEY EXECUTIVES
  • TABLE 113. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 114. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 115. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 116. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. BIOGEN INC.: KEY EXECUTIVES
  • TABLE 118. BIOGEN INC.: COMPANY SNAPSHOT
  • TABLE 119. BIOGEN INC.: OPERATING SEGMENTS
  • TABLE 120. BIOGEN INC.: PRODUCT PORTFOLIO
  • TABLE 121. BIOGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNOMODULATORS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL IMMUNOMODULATORS MARKET
  • FIGURE 3. SEGMENTATION IMMUNOMODULATORS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN IMMUNOMODULATORS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIMMUNOMODULATORS MARKET
  • FIGURE 11. IMMUNOMODULATORS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. IMMUNOMODULATORS MARKET FOR IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. IMMUNOMODULATORS MARKET FOR IMMUNOSTIMULANTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. IMMUNOMODULATORS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. IMMUNOMODULATORS MARKET FOR ONCOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. IMMUNOMODULATORS MARKET FOR RESPIRATORY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. IMMUNOMODULATORS MARKET FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. IMMUNOMODULATORS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 23. COMPETITIVE DASHBOARD
  • FIGURE 24. COMPETITIVE HEATMAP: IMMUNOMODULATORS MARKET
  • FIGURE 25. TOP PLAYER POSITIONING, 2024
  • FIGURE 26. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 27. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 28. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 29. AMGEN, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. AMGEN, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. AMGEN, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 32. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. MERCK AND CO., INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. ELI LILLY AND COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. BIOGEN INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. BIOGEN INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. BIOGEN INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Immunomodulators Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved